CAMBRIDGE, Mass-In 1997, officials from pharmaceutical giant Eli Lilly decided to take a chance on a new biotechnology company, Vertex, by investing some $10 million.
Five years later, the two companies have come together to announce Phase I clinical trial expectations of a new compound they have created to combat hepatitis C. Researchers at the companies have developed a protease inhibitor compound that limits the reproductive ability of the hepatitis C virus-similar to protease inhibitors currently being used to fight HIV/AIDS.
Lilly paid a $5 million milestone payment to Vertex after the drug candidate was selected. Along with other pharmaceutical companies, Lilly has interest in the new project because more than 2.7 million Americans suffer from hepatitis C infection. The virus causes liver inflammation, cirrhosis, liver failure, and liver cancer. Some 8,000 Americans died annually from hepatitis C.
Current treatments include immunity-boosting drugs that do not work for all patients.
Information from www.sfgate.com
Beyond the Surface: Rethinking Environmental Hygiene Validation at Exchange25
June 30th 2025Environmental hygiene is about more than just shiny surfaces. At Exchange25, infection prevention experts urged the field to look deeper, rethink blame, and validate cleaning efforts across the entire care environment, not just EVS tasks.
A Controversial Reboot: New Vaccine Panel Faces Scrutiny, Support, and Sharp Divides
June 26th 2025As the newly appointed Advisory Committee on Immunization Practices (ACIP) met for the first time under sweeping changes by HHS Secretary Robert F. Kennedy Jr, the national spotlight turned to the panel’s legitimacy, vaccine guidance, and whether science or ideology would steer public health policy in a polarized era.
Getting Down and Dirty With PPE: Presentations at HSPA by Jill Holdsworth and Katie Belski
June 26th 2025In the heart of the hospital, decontamination technicians tackle one of health care’s dirtiest—and most vital—jobs. At HSPA 2025, 6 packed workshops led by experts Jill Holdsworth and Katie Belski spotlighted the crucial, often-overlooked art of PPE removal. The message was clear: proper doffing saves lives, starting with your own.